Viewing Study NCT06854159


Ignite Creation Date: 2025-12-24 @ 2:39 PM
Ignite Modification Date: 2025-12-26 @ 10:17 AM
Study NCT ID: NCT06854159
Status: RECRUITING
Last Update Posted: 2025-09-29
First Post: 2025-02-25
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
Sponsor: Joseph Tuscano
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Recurrent Diffuse Large B-Cell Lymphoma View
None Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma View
None Refractory Diffuse Large B-Cell Lymphoma View
None Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma View
Keywords: